POINT Biopharma Provides Update on Manufacturing, Supply Chain and Late-Stage Programs

Retrieved on: 2022-02-01 19:30:09

Tags for this article:

Radiopharmaceuticals

Physical sciences

Medicine

Chemistry

Forward-looking statement

Lutetium (177Lu) oxodotreotide

Actinium-225

Neuroendocrine tumor

Radiation therapy

Lutetium (177Lu) chloride

Click the tags to see associated articles and topics

POINT Biopharma Provides Update on Manufacturing, Supply Chain and Late-Stage Programs. View article details on hiswai:

Excerpt

INDIANAPOLIS, Ind., Feb. 01, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the ...

Article found on: www.globenewswire.com

View Original Article